CLL
Conference Coverage
‘Superior’ CLL regimen cuts chemo in half
Where chemo is still used to treat CLL, this three-cycle regimen combined with ibrutinib and obinutuzumab shows progression-free and overall...
News
FDA approves liso-cel as second-line therapy for LBCL
Liso-cel could now become a “new standard of care for patients after failure of first-line therapy,” offering significantly improved outcomes for...
Conference Coverage
Venetoclax combos prolong progression-free CLL survival
Time-limited targeted therapy with venetoclax plus obinutuzumab outperforms chemoimmunotherapy for CLL progression-free survival.
Conference Coverage
Studies address ibrutinib bleeding risk in patients with CLL receiving Mohs surgery
Mohs surgeons may commonly find themselves treating patients with these unique considerations.
From the Journals
Phase-3 study: Leukemia patients live longer with ibrutinib
RESONATE-2 trial data show durable improvements for chronic lymphocytic leukemia (CLL) patients, even those with high-risk genomic features.
Feature
Third-generation Black woman physician makes cancer research history
African American surgeon helped found ASCO and collaborated with her father to achieve lasting breakthroughs in chemotherapy.
Feature
Ex–hospital porter a neglected giant of cancer research
An Indian immigrant who once emptied bedpans in a Boston hospital went on to become the “father of chemotherapy.”
From the Journals
‘Agony of choice’ for clinicians treating leukemia
Novel targeted therapies emerge as frontline options while chemoimmunotherapy “fades into the background.”
Conference Coverage
Zanubrutinib shows worth against standard CLL drugs
New CLL drug demonostrates its efficacy in the crowded field of CLL treatment options.
Feature
When CPI fails, HL patients should get timely allo-HCT
New data suggest that physicians should refer Hodgkin lymphoma patients for allogeneic HCT without delay when PD-1 treatments fail.
Feature
Survivor’s story foreshadows one of oncology’s greatest successes
In 1992, a young New Yorker was among the first Hodgkin lymphoma patients to undergo a successful bone marrow transplant. Three decades later,...